Heron Therapeutics reported $54.57M in Stock for its fiscal quarter ending in December of 2022.





Stock Change Date
ALKERMES USD 261.1M 37.86M Sep/2026
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
Amarin USD 158.85M 5.22M Sep/2026
ANI Pharmaceuticals USD 136.41M 6.74M Sep/2026
Anika Therapeutics USD 28.56M 5.73M Jun/2026
Arrowhead Research USD -173.08M 173.08M Dec/2024
Eisai JPY 272.61B 15.06B Sep/2026
Emergent BioSolutions USD 328.9M 25.2M Dec/2023
GlaxoSmithKline GBP 6.28B 125M Jun/2026
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Insmed USD 163.95M 21.56M Sep/2026
Ligand Pharmaceuticals USD 14.51M 4.24M Sep/2026
Merck USD 6.16B 43M Sep/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 66.1M 38.1M Sep/2026
Omeros USD 712K 266K Sep/2021
Pacira USD 3.83B 3.69B Sep/2026
Regeneron Pharmaceuticals USD 2.89B 189.7M Sep/2026
Roche Holding CHF 7.6B 9M Jun/2025
Ultragenyx Pharmaceutical USD 59M 0 Sep/2026
Veracyte USD 25.82M 3.16M Sep/2026
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026